


CLAIMS

1. A compound of the formula:



in which:

- 5 a. M is NZ or O;
 b. Z is represented by H or C₁-C₄ alkyl;
 c. R¹ is represented by hydrogen, (C₁-C₂)alkyl, optionally substituted with one or more halogens, or (C₁-C₂)alkoxy, optionally substituted with 1 or more halogens;
 10 d. R² is absent, or may represent up to 2 substituents selected from the group consisting of halogen, nitrile, hydroxy, (C₁-C₄)alkyl, (C₂-C₄)alkenyl, (C₂-C₄)alkynyl, (C₁-C₄)alkoxy, (C₁-C₂)alkyl substituted with 1 or more halogens, (C₁-C₂)alkoxy substituted with one or more halogens, SR⁴, and NR⁴R⁵;
 15 e. A is represented by -S(O₂);
 f. B completes a heterocyclic ring;
 g. R³ may be absent, or may represent up to 2 substituents selected from the group consisting halogen, hydroxy, nitrile, (C₁-C₄)alkoxy, (C₁-C₄)alkyl, optionally substituted heterocyclic, optionally substituted heteroaryl, optionally substituted phenyl, -[CH₂]_mC(O)OR⁴, -[CH₂]_mC(O)R⁴, -[CH₂]_mC(O)NR⁴R⁵, (C₁-C₄)alkylR⁶, -[CH₂]_n-Y[-CH₂]_m-X-[CH₃]_q, (C₃-C₈)cycloalkyl, and -SR⁴ -
 20 h. R⁴ is represented by hydrogen, (C₁-C₄)alkyl, optionally substituted benzyl, optionally substituted phenyl, optionally substituted

heteroaryl, or optionally substituted heterocyclic or R⁴ and R⁵ together with the adjacent nitrogen atom can combine to form a heterocyclic or heteroaryl ring;

- 5 i. R⁵ is represented by hydrogen, optionally substituted phenyl, (C₁-C₄)alkyl, or optionally substituted benzyl;
- j. R⁶ is represented by optionally substituted phenyl, optionally substituted heteroaryl, or optionally substituted heterocyclic;
- k. n is an integer selected from 1, 2, 3, or 4;
- l. Y is absent, or is represented by O, C(O),OH, SH, or S;
- 10 m. m is represented by an integer selected from 0, 1, 2, 3, or 4;
- n. X is absent, or is represented by O, C(O),OH, SH or S; and
- o. q is represented by the integer 0 or 1, and; the pharmaceutically acceptable salts, solvates, and prodrugs thereof with the provision that if both X and Y are present, then M is not zero.
- 15 2. The compound of claim 1 in which R¹ is represented by trifluoromethyl.
3. The compound of claim 2 in which M is NZ, in which Z is hydrogen.
4. The compound according to claim 2 in which B complete a 5 or 6 member sulfur containing heterocyclic ring.
5. The compound according to claim 3 in which B complete a 5 or 6 member sulfur containing heterocyclic ring.
- 20 6. The compound according to claim 2 in which B complete a 5 or 6 member nitrogen containing heterocyclic ring
7. The compound according to claim 2 in which B complete a 5 or 6 member nitrogen containing heterocyclic ring

PC25091A

8. The compound according to claim 2 in which B complete a 5 or 6 member oxygen containing heterocyclic ring
9. The compound according to claim 2 in which B complete a 5 or 6 member oxygen containing heterocyclic ring

5

- 10 10. The compound according to claim 2 in which B is selected from the group consisting of azocane, piperidine, piperazine, pyrrolidine, isoquinoline, thiazolidine, morpholine, azepane, and azetidine.
11. The compound according to claim 3 in which B is selected from the group consisting of azocane, piperidine, piperazine, pyrrolidine, isoquinoline,
15 thiazolidine, morpholine, azepane, and azetidine.
12. The compound according to claim 1 in which said compound is selected from the group consisting of:

6-(Azocane-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;

20 6-(4-Pyrrolidin-1-ylpiperidine-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;

6-[4-(4-Methoxyphenyl)-3-methylpiperazine-1-sulfonyl]-4-trifluoromethyl-1H-quinolin-2-one;

1-(2-Oxo-4-trifluoromethyl-1,2-dihydroquinoline-6-sulfonyl)piperidine-4-carboxylic acid ethyl ester;

PC25091A

- 6-(4-Hydroxy-4-thiophen-2-ylpiperidine-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;
- 6-(4-Furan-2-ylmethylpiperazine-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;
- 5 6-(1,3-Dihydroisindole-2-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;
- 1-(2-Oxo-4-trifluoromethyl-1,2-dihydroquinoline-6-sulfonyl)pyrrolidine-2-carboxylic acid methyl ester;
- 10 6-{4-[2-(2-Hydroxyethoxy)-ethyl]piperazine-1-sulfonyl}-4-trifluoromethyl-1H-quinolin-2-one;
- 6-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinoline-2-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;
- 6-(1,4-Dioxo-8-azaspiro[4.5]decane-8-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;
- 15 6-[4-(2-Oxo-2-pyrrolidin-1-ylethyl)piperazine-1-sulfonyl]-4-trifluoromethyl-1H-quinolin-2-one;
- 6-(4-Methylpiperidine-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;
- 20 6-(3-Hydroxymethylpiperidine-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;
- 6-(Thiazolidine-3-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;

PC25091A

- 6-(4-Pyridin-4-ylpiperazine-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;
- 6-(4-Phenylpiperazine-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;
- 5 6-[2-(2-Hydroxyethyl)-piperidine-1-sulfonyl]-4-trifluoromethyl-1H-quinolin-2-one;
- 6-(2-Hydroxymethyl-pyrrolidine-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;
- 10 6-(Octahydroquinoline-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;
- 6-[4-(2-Thiophen-2-ylethyl)piperazine-1-sulfonyl]-4-trifluoromethyl-1H-quinolin-2-one;
- 6-(Pyrrolidine-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;
- 15 6-(2,6-Dimethylmorpholine-4-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;
- 6-(2-Oxa-5-azabicyclo-[2.2.1]heptane-5-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;
- 6-(Azepane-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;
- 20 6-(2-Methylpiperidine-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;
- 6-(4-Cyclopentylpiperazine-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;

PC25091A

- 6-(Azetidine-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;
- 6-(4-Pyridin-2-ylpiperazine-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;
- 5 6-(2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;
- 6-(2,3,5,6-Tetrahydro-[1,2']bipyrazinyl-4-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;
- 10 1-(1-Methyl-2-oxo-4-trifluoromethyl-1,2-dihydroquinoline-6-sulfonyl)piperidine-4-carboxylic acid ethyl ester;
- 6-(1,3-Dihydroisoindole-2-sulfonyl)-1-methyl-4-trifluoromethyl-1H-quinolin-2-one;
- 6-(4-Ethylpiperazine-1-sulfonyl)-1-methyl-4-trifluoromethyl-1H-quinolin-2-one;
- 15 6-{4-[2-(2-Hydroxyethoxy)-ethyl]piperazine-1-sulfonyl}-1-methyl-4-trifluoromethyl-1H-quinolin-2-one;
- 1-Methyl-6-(thiazolidine-3-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;
- 20 1-Methyl-6-(octahydro-quinoline-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;
- 6-(Azepane-1-sulfonyl)-1-methyl-4-trifluoromethyl-1H-quinolin-2-one;

PC25091A

6-(2,6-Dimethylmorpholine-4-sulfonyl)-1-methyl-4-trifluoromethyl-1H-quinolin-2-one; and

6-(3,4-Dihydro-2H-quinoline-1-sulfonyl)-1-methyl-4-trifluoromethyl-1H-quinolin-2-one.

5

13. The compound according to Claim 1 in which said compound is selected from the group consisting of 6-(thiazolidine-3-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one, 6-(azocane-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one, and 6-[4-(piperidine-1-sulfonyl)]-4-trifluoromethyl-1H-quinolin-2-one.
10
14. A method for inhibiting activation of the androgen receptor comprising administering an effective amount of a compound according to claim 1 to a patient in need thereof.
15
15. A method for the alleviating a condition selected from the group consisting of alopecia, acne, oily skin, prostate cancer, hirsutism, and benign prostate hyperplasia, comprising administering a compound according to claim 1 to a patient in need thereof.
16. A pharmaceutical composition comprising a compound according to claim 1 in admixture with 1, or more, pharmaceutically acceptable excipients.
20
17. A topical pharmaceutical formulation comprising a compound according to claim 1 in admixture with 1, or more, pharmaceutically acceptable excipients suitable for dermal application.
25
18. An article of manufacture comprising a compound according to claim 1 packaged for retail distribution, which advises a consumer how to utilize

PC25091A

the compound to alleviate a condition selected from the group consisting of acne, alopecia, and oily skin.